A r t i c l e s a genetic component to the disease 8, 16 . So far, linkage studies have identified several loci predisposing individuals to IgA nephropathy, but the underlying genes are not known 8, [16] [17] [18] . A single, unreplicated genomewide association study (GWAS) in a small European cohort (533 cases) has reported association of IgA nephropathy with the major histocompatibility complex (MHC) 19 .
We report a GWAS for IgA nephropathy in a cohort of 3,144 IgA nephropathy cases of Chinese and European ancestry, leading to the identification of five loci for this disease.
RESULTS

Study design and genotyping of discovery cohort
To detect loci conferring susceptibility to IgA nephropathy, we carried out a twostage GWAS ( Table 1 ). In the discovery phase, we carried out genomewide genotyping on the Illumina 610 Quad platform in 1,228 biopsyproven IgA nephropathy cases and 966 healthy controls of Chinese Han ancestry recruited from Beijing ( Table 1 and Supplementary  Table 1) . We further evaluated the top signals in the discovery phase in an independent cohort of Han Chinese descent (Shanghai cohort, 740 cases and 750 controls) and a European cohort of Italian and North American origin (combined by stratified analysis, 1,273 cases and 1,201 controls). Subsequently, we analyzed the Beijing, Shanghai and European cohorts together to identify genomewide significant loci.
Genome-wide association analysis
In analysis of genomewide genotyping data, we applied quality con trol filters, leading to elimination of 5% of samples because of low call rate, duplication, cryptic relatedness or gender mismatch and 16.8% of markers primarily because of low minor allelic frequency (<0.01, see Supplementary Note and Supplementary Table 2) . After quality control, the genotyping call rate was 0.9992. We next applied the standard 1degreeoffreedom CochranArmitage trend test to analyze 498,322 SNPs in the discovery cohort of 1,194 cases (650 males and 544 females, average age 31.1 years) and 902 controls (608 males and 294 females, average age 31.5 years). The quantilequantile plot showed no global departure from the expected distribution of P values and the inflation factor (λ) was 1.024, indicating negligible popu lation stratification ( Supplementary Fig. 1 and Fig. 1 ). Accordingly, principal component analysis (PCA) indicated that cases and controls were matched along the axes of statistically significant principal components, and PCA correction did not substantially change the distribution of the association statistic or the genomic inflation factor (λ = 1.022; Supplementary Fig. 2 and Supplementary Table 3) . We concluded that our association results were not biased by differences in ancestry or population structure between cases and controls.
The genomewide association analysis showed 27 SNPs exceeding genomewide thresholds for significance (P ≤ 5 × 10 −8 ; Fig. 1) . These 27 signals all resided in a 0.54Mb interval within the MHC on chromosome 6p21, with the top signal at rs9275596 (P = 1.9 × 10 −12 ). Notably, 14 MHC SNPs with suggestive P values (P = 5 × 10 −6 to P = 1 × 10 −4 ) showed little or no linkage disequilibrium (LD) with rs9275596 ( Fig. 2a) .
Follow-up of top signals from discovery stage
After we removed MHC SNPs, additional loci remained that showed departure from the expected Pvalue distribution. We ranked signals on the basis of the false discovery rate and chose to follow up loci with P ≤ 1.3 × 10 −5 , corresponding to a Q value ≤ 0.10 ( Supplementary  Fig. 3 ) 20 . Power calculations indicated that this strategy would pro vide 80% power to detect loci with allelic frequencies >0.10 and rela tive risk >1.5 with genomewide significance (P < 5 × 10 −8 ) in the combined cohort (Supplementary Table 4 ). In total, 65 SNPs from ten distinct loci met these criteria (including three potentially inde pendent loci in MHC and two in the chromosome 22q12.2 interval). We genotyped the topscoring SNPs and one additional SNP from each of these intervals in followup cohorts (20 SNPs total in 3,870 individuals after quality control; Table 1 ). We carried out tests of association within each cohort, followed by a combined analysis with the discovery cohort using Mantel's extension of CochranArmitage trend test ( Table 2 and Supplementary Table 5) .
Five of the ten loci selected for follow up surpassed the threshold for significant genomewide association: three loci within 6p21, one locus at 1q32 and one locus at 22q12.2 ( Table 2 and Supplementary  Tables 5,6 ). Each signal had significant association with consistent effect size for the same risk allele in each individual cohort, with little evidence for heterogeneity.
The strongest association in the combined cohort was located within a ~170kb interval that includes HLA-DRB1, HLA-DQA1 and HLA-DQB1 (rs9275596, odds ratio (OR) = 0.63, P = 1.6 × 10 −26 ). This SNP has genomewide significance with a consistent effect size in each cohort ( Table 2 and Fig. 2b ) and has strong supporting association from a nearby SNP in strong LD (rs2856717).
This locus, however, did not explain all of the signal at 6p21. Conditioning for the effect of rs9275596 eliminated evidence for association for the majority of SNPs in close proximity, however two distinct loci maintained genomewide significance. The second inde pendent locus is defined by rs9357155 (which has an r 2 = 0.01 for correlation with rs9275596 in the combined cohort) and has an OR of 0.74 and a P value of 6.9 × 10 −9 for association with IgA nephropathy after conditional analysis ( Table 3 and Fig. 2c ). This SNP lies in a ~100kb segment of LD and lies 128 kb centromeric to rs9275596. This LD segment contains the genes TAP2, TAP1, PSMB8 and PSMB9, and the supporting SNP in this region (rs2071543) is a missense variant in PSMB8 (p.Gln49Lys) that is at a position completely conserved Tables 7,8 ).
After we conditioned for the effects of both rs9275596 and rs9357155, we found that a third locus within MHC, defined by rs1883414, which lies 400 kb centromeric to rs9275596 (and which showed r 2 = 0.005 and r 2 = 0.002 with rs9275596 and rs9357155, respectively), showed a conditioned OR of 0.77 and P value of 3.1 × 10 −8 for association ( Table 3 ). This signal, in the region of HLA-DPA1, HLA-DPB1 and HLA-DPB2, is supported by a second SNP (rs3129269) and showed consistent effect size across cohorts (Tables 2,3, Fig. 2d , and Supplementary Tables 7,8 ).
To better delineate the risk associated with the MHC region and detect potential functional variants, we imputed classical HLA alleles in the discovery cohort 21 (Supplementary Table 9 ). This showed a genomewide significant association with a proteinaltering variant of known functional importance, the DQB1*0602 allele (OR = 0.47, P = 6.6 × 10 −9 ). DQB1*602 is in strong LD with another functional allele, DRB1*1501, but conditional analysis suggested that DQB1*602 best explains this association signal (Supplementary Table 10 ). The strength of the DQB1*602 association is probably underestimated because of the limitations of current imputation algorithms (sensitivity of 56.6% for detection of the DQB1*602 allele; Supplementary Table 11) .
A major signal outside the MHC locus resided in a 100kb segment on chromosome 1q31q32.1 containing CFH (encoding comple ment factor H) and the related CFHR3, CFHR1, CFHR4, CHFR2 and CFHR5 genes (rs6677604, OR = 0.68, P = 3.0 × 10 −10 in the combined cohort). This locus was also the top signal in our genomewide copy number polymorphism (CNP) analysis ( Supplementary Fig. 4 and Supplementary Table 12 ). The top SNP, rs6677604, is located in intron 12 of CFH and is supported by multiple highly correlated SNPs ( Fig. 3a and Table 2 ). After controlling for rs6677604, there were no other independent signals in the entire CFH region. The association results at rs6677604 were far less significant under a recessive model (P = 5.6 × 10 −5 ), supporting an additive risk. The rs6677604 A allele is protective in all three cohorts but has a much higher allele frequency in Europeans (0.23 in European controls versus 0.07 in Chinese con trols; Table 2 ). This allele perfectly tags a common deletion spanning CFHR1 and CFHR3 (CFHR1,3∆) 22, 23 . We confirmed the association of the rs6677604 A allele with CFHR1,3∆ in our cohort: PCR of multiple amplicons within CFHR1 and CFHR3 failed, and we did not A r t i c l e s detect the CFHR1 protein in serum from all AA homozygotes tested ( Supplementary Fig. 5 ). We evaluated evidence for association of IgA nephropathy with alleles in CFH that confer risk of agerelated macular degeneration (AMD) and found no contribution to risk (for example, the p.Tyr402His variant, tagged by rs10801555, showed OR = 1.0 and P = 0.99 in discovery cohort; Fig. 3b ). Haplotypebased analysis in the Beijing discovery cohort indicated protection by the haplotype containing the rs6677604 A allele (OR = 0.56, P = 1 × 10 −6 versus all other haplotypes in the discovery cohort; Fig. 3b and Supplementary Fig. 6 ) but no significant effect of other haplotypes. The fifth signal in the GWAS resided in an intronic SNP in HORMAD2 on chromosome 22.q12.2 (rs2412971, OR = 0.80, P = 1.9 × 10 −9 ) and was supported by a second SNP within 35 kb of this sig nal (rs2412973, OR = 0.80, P = 4.5 × 10 −9 ). After controlling for rs2412971, there were no other independent signals in this region. The association extends across a large LD segment that encompasses genes including HORMAD2, MTMR3, LIF and OSM (Fig. 3c) .
Cumulative effects on disease risk
To determine the cumulative risk conferred by these loci, we computed a genetic risk score, calculated as the weighted sum of the number of protective alleles multiplied by the log of the OR for each of the indi vidual loci (Table 4 and Supplementary Tables 13,14) . The disease risk varied up to tenfold between individuals with no protective alleles and those with five or more. The risk score model was similar in all cohorts and collectively explained 5-7% of the variation in disease risk in the Chinese cohorts and ~4% of the risk in the European cohort ( Table 4 ). The risk score did not reproducibly correlate with any of the parameters of disease severity, such as estimated glomerular filtration rate, degree of proteinuria or histologic severity grade.
Most notably, consistent with the higher prevalence of IgA nephro pathy in Asians, the frequency of protective alleles was significantly lower in the Chinese cohort compared with the European group. The differences in distribution of protective alleles were highly significant between the Asian and European cohorts ( Fig. 4a , P = 4.8 × 10 −72 and P = 6.4 × 10 −60 for differences within cases and controls, respectively). To confirm this finding in independent populations, we examined three HapMap groups and similarly found that frequencies of risk alleles correlate with disease frequency among these populations: risk allele frequencies were highest in Asians, intermediate in Europeans and lowest in Africans ( Fig. 4b and Supplementary Fig. 7 ). For example, the protective allele at the chromosome 1 locus has a fre quency of 0.08 in Asians, 0.24 in Europeans and 0.49 in Africans.
DISCUSSION
In this GWAS, we identified five loci imparting significant and con sistent effects on the risk of IgA nephropathy across three independent cohorts. These five loci explained up to a tenfold variation in interin dividual risk and cumulatively accounted for 4-7% of the disease vari ance. The effect sizes at these loci are relatively large and consistent across the European and Chinese cohorts, with four having inverse OR ≥ 1.4, which is comparable to those detected in earlier studies of autoimmune or inflammatory diseases 21, [24] [25] [26] [27] [28] [29] [30] . The risk allele frequen cies also strongly paralleled the prevalence of IgA nephropathy among different populations. We detected a major signal in the MHC region, which was identified but not localized in a recent GWAS with 533 affected subjects 19 . Our study of the markedly larger cohorts reported here showed that this signal originated from three distinct loci within HLA; we also identified two nonHLA loci. Evidence supporting the presence of three independ ent risk loci on chromosome 6p21 includes their position within distinct LD segments, as well as genomewide significance after conditioning for the other two loci, with consistent effects within each cohort.
The strongest HLA signal was in the region of HLA-DRB1 and HLA-DQB1. Imputation of classical alleles suggested that this sig nal is fully or partially conveyed by a strong protective effect of the DRB1*1501-DQB1*0602 haplotype; the strength of this association was probably underestimated by limitations of imputation. This haplotype is relatively common in the European and Asian popula tions (frequency, ~0.1-0.2) and, in contrast to its protective effect for IgA nephropathy, has been associated with increased risk of systemic lupus erythematosus 25 , multiple sclerosis 31 , narcolepsy 32 and hepatotoxicity from COX2 inhibitors 30 but is also highly protec tive for type I diabetes mellitus 26 . This haplotype is also protective in selective IgA deficiency 27 , yet we found no association with IgA levels at this locus among cases (Supplementary Table 15) . This region has a complex LD structure, and our conditional analysis suggests the possibility of an independent signal within this region (at rs9275424; Supplementary Tables 7,8 ). Highresolution map ping and direct genotyping of classical alleles will be required to further dissect this interval and identify the functional variant(s).
The second independent interval at 6p21 contained TAP2, TAP1, PSMB8 and PSMB9, interferonregulated genes implicated in antigen generation and processing for presentation by MHC I molecules; they also have an important role in modulation of cytokine production and cytotoxic Tcell response 33, 34 . PSMB8 expression is increased in peripheral blood mononuclear cells from individuals with IgA nephropathy, motivating further investigation 35 . To our knowledge, this locus has not been identified in any earlier GWAS.
The third signal at 6p21 comprised the HLA-DPA1, HLA-DPB1 and HLA-DPB2 genes. This locus is associated with risk of chronic hepatitis B infection 29 (a major clinical problem in China) and sys temic sclerosis stratified for antibody to DNA topoisomerase I or autoantibodies to centromeres 31 , but the risk alleles associated with these phenotypes are not in LD with any of the IgA nephropathy risk alleles.
CFH has a critical role in dampening the alternative complement cascade through inhibition of the C3 and C5 convertases 36 . The func tions of the CFHrelated proteins are less well understood 36, 37 . Loss offunction mutations in CFH produce uncontrolled C3 activation, leading to membranoproliferative glomerulonephritis type II, which is pathologically distinct from IgA nephropathy 36 . Other rare CFH mutations can produce hemolytic uremic syndrome, a thrombotic dis order 36 , whereas distinct common haplotypes predispose individuals to AMD and susceptibility to meningococcal infection [22] [23] [24] . Notably, the CFH haplotype bearing the CFHR1,3∆ variant may be protective in AMD, but detection of an independent effect has been complicated A r t i c l e s because of the presence of additional haplotypes imparting both high and low risk 22, 23 . Here we found an unambiguous protective effect of the CFHR1,3∆-containing haplotype in IgA nephropathy, strongly suggesting that CFHR1,3∆ is the functional variant. Nevertheless, it is unclear how loss of CFHR1 and/or CFHR3 may confer protection for IgA nephropathy. The protective effects may be due to the com peting roles of CFH and CFHR1 proteins 37 , such that loss of CFHR1 enhances CFH effects, reducing inflammation at tissue surfaces. The chromosome 22q12.2 locus spans a large interval that con tains OSM and LIF, encoding cytokines implicated in mucosal immunity and inflammation. Notably, inactivation of Osm leads to autoimmune glomerulonephritis in mouse 38 . The functions of other genes such as HORMAD2 and MTMR3 have not been as well char acterized 39 . In addition, the rs2412973 A allele, which is protective for IgA nephropathy, has also been associated with increased risk of earlyonset inflammatory bowel disease and altered expression of MTMR3 expression in individuals with ulcerative colitis 28 . This find ing is notable given the known clinical association between inflam matory bowel disease and secondary forms of IgA nephropathy, but the underlying signal within this locus remains to be clarified. Lastly, the protective allele at this locus is also associated with lower serum IgA levels among cases (P = 3.9 × 10 −3 ; Supplementary Table 15 and Supplementary Fig. 8) .
Many of the protective alleles for IgA nephropathy have been implicated as risk factors for other immunemediated and infectious disorders, suggesting that complex selection pressures (potentially balancing selection) may influence the frequencies of these alleles among world populations. Statistical proof of balancing selection on allele frequencies or genotypes may be particularly challenging if alleles have been maintained in the population over very long evo lutionary periods. Notably, a recent genomewide survey detected a signal of selection in the vicinity of the CFH gene cluster 40 , and there is a large difference in the frequency of the rs6677604 A allele among world populations (Supplementary Table 16 ).
The loci identified in this study clarify the genetic architecture of sporadic IgA nephropathy, identifying new pathogenic pathways and connections to other immunemediated disorders. On the basis of our power calculations, we identified virtually all loci imparting an OR ≥ 1.5 in the Chinese discovery cohort, but additional loci with large effects may be present among Europeans. Considering the effective ness of GWAS for studies of immunologic disorders 22, [27] [28] [29] [30] [31] 41 and the increased power imparted by larger sample size 42 , genomewide examination of larger cohorts will probably define additional genetic components of IgA nephropathy.
URLs. HLA genotype data of the HapMap Chinese samples, https:// www.sanger.ac.uk/HGP/Chr6/ng2006data/; IBD software, http:// www1.cs.columbia.edu/~itsik/hla_ibd/; HapMap, http://hapmap. ncbi.nlm.nih.gov/.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
ONLINE METHODS
Genome-wide genotyping, genotype quality control and primary association analyses. Study populations, genomewide genotyping and genotype quality control are described in the Supplementary Note and Supplementary  Tables 1 and 2 . After quality control analysis, the discovery cohort consisted of 1,194 cases and 902 controls genotyped with the Illumina Human 610 Quad BeadChip. The primary genomewide association analyses were carried out using PLINK v1.07 (ref. 44 ). We selected a standard 1degreeoffreedom CochranArmitage trend test as the primary association test, as it demonstrates greater robustness to deviations from HardyWeinberg equilibrium compared with its alternatives. We estimated the perallele ORs and 95% confidence intervals for all tested SNPs. The genomewide distributions of P values were examined using quantilequantile plots, before and after exclusion of the HLA region (Supplementary Fig. 1 ). The assessment of population stratification in the discovery cohort is described in Supplementary Note, Supplementary Table 3 and Supplementary Figure 2. False discovery rate and power analysis. The calculation of positive false discovery rate (pFDR) was carried out using the Qvalue package (R). The proportion of SNPs that were truly null (Πo) was estimated at 0.991 using the empirical distribution of genomewide P values 20 . The Q value of 0.10 (pFDR of 10%) corresponded to the P value of 1.3 × 10 −5 ( Supplementary Fig. 3 ). This Qvalue threshold defined 65 top SNPs that were subsequently analyzed for replication. The power analysis was carried out using methods described 45 . The calculations were carried out under the following assumptions: a disease prevalence of 1%; an additive risk model for stage I (discovery) with sample size of 1,000 cases and 1,000 controls and stage II (followup) with sample size of 2,000 cases and 2,000 controls; a followup significance threshold of 1.3 × 10 −5 ; and joint (stage I and II) significance level of 5 × 10 −8 . The joint power of our study design (Supplementary Table 4) was calculated for a range of disease allele frequencies (0.10-0.50) and effect sizes (genotypic risk ratio 1.10-1.80). The effect sizes detectable at α = 5 × 10 −8 and a power of 0.80 in the joint analysis were estimated using CaTS software 45 .
Selection of SNPs for follow-up. The 65 SNPs that reached our Qvalue threshold were first clustered into ten distinct loci on the basis of their physi cal location and regional patterns of LD. The correctness of genotype calls was verified for each SNP individually by visual inspection of the Illumina cluster plots. Conditional logistic regression analysis was carried out to confirm cor rect SNP grouping and detect independence signals. These analyses suggested three distinct loci on chromosome 6p21 and two distinct loci on chromosome 22q12.2. The SNPs with the lowest P value within each locus were selected for follow up. The selection of the second SNP for backup genotyping was based mainly on its strength of association, high LD with the topscoring SNP in European and Chinese HapMap populations, robustness of Illumina clustering plots and high genotyping rate. In total, we selected 20 representative SNPs for genotyping in 2,013 cases and 1,951 controls recruited for stage 2 of the study. Genotyping and genotype quality control in the followup cohorts is described in Supplementary Note. Association analyses across multiple cohorts. Results across multiple cohorts were combined using a stratified trend test with Mentel's extension of the CochranArmitage test (snpMatrix package, R) 46 . We tested for heterogeneity across cohorts with the heterogeneity index (I 2 ), and by carrying out Cochran's Q heterogeneity test. To ensure findings were robust to methodology, we also combined the perallele effect estimates using CochranMantelHaenszel stratified analysis, as well as an inverse varianceweighted method under a fixedeffects model. The results were concordant regardless of the meta analytic method used.
Conditional analyses.
We carried out stepwise logistic regression after con trolling for the genotypes of the conditioning SNPs using PLINK (v1.07). The adjusted (conditioned) effect estimates were then combined across cohorts by adding cohort information as an additional covariate in the stratified analysis ( Table 3 and Supplementary Table 8) . A similar approach was used for the conditional analysis of classical HLA alleles (Supplementary Table 10) .
Haplotype-based association at CFH locus. These analyses were carried out in PLINK v1.07. Haplotypes were phased across the CFH locus in the Beijing cohort ( Fig. 3b and Supplementary Fig. 6 ) and haplotype frequen cies were estimated in the cases and controls separately, as well as jointly in the entire cohort. Only the haplotypes with overall frequency >1% were included in association analyses. The P values were derived for tests of association of one haplotype versus all others. The ORs and the correspond ing 95% confidence intervals were estimated in reference to the AMD risk haplotype (H1; Fig. 3b) , which has an identical frequency between cases and controls.
Imputation and association analysis of classical HLA alleles. The HLA classical alleles at DQB1, DQA1 and DRB1 loci were imputed on the basis of the genotype data from the Beijing cohort (Supplementary Tables  9,10 ). In short, the genotype data were first phased using BEAGLE 47 and pairwise inflammatory bowel disease status was determined using GERMLINE software 48 . The HLA classical allele status and genotype data of the HapMap Han Chinese individuals were used as a reference panel (see URLs) 21 . The imputation was carried out using the HLAviaIBD soft ware (see URLs). The accuracy of the imputation procedure was tested by direct sequencing of the informative coding segments of HLA-DQB1 gene in a random subset of 420 samples. This demonstrated that imputation had 57% sensitivity and 96% specificity for identifying the HLA-DQB1*602 alleles (Supplementary Table 11 ).
Risk score discovery and validation. Among the five independent regions of association, alleles with lower frequency conveyed a protective effect. Therefore, the risk score model was based on protective genotypes for the top five independent and most strongly associated SNPs (rs9275596, rs9357155, rs1883414, rs2412971 and rs6677604). The risk score was calculated as a weighted sum of the number of protective alleles at each locus multiplied by the log of the OR for each of the individual loci for a specific cohort. Only individuals with nonmissing genotypes for all ten alleles were included in this analysis ( Table 4 and Supplementary Table 13 ). The predictive risk score models were built using association results for each of the three modelbuild ing cohorts and were validated by testing their predictive properties against all other cohorts (target cohorts, Supplementary Table 14 and Supplementary  Fig. 7) . The percentage of the total variance in disease state explained by the risk score was estimated by Nagelkerke's pseudo r 2 from the logistic regression model with the risk score as a quantitative predictor and disease state as an outcome. The Cstatistic was estimated as an area under the receiver operating characteristic curve provided by the above logistic model. These analyses were carried out with SPSS Statistics version 17.0.
Distributions of protective alleles. Each individual study participant was scored for the number of protective alleles and the distributions of protec tive alleles were compared between groups of various ancestries (Fig. 4) . Only individuals with complete genotype information were included. Because relatively few individuals had five or more protective alleles, they were binned into a single category for the purpose of statistical testing and a χ 2 goodnessoffit test was used to derive P values. Analysis of the HapMap release 23 data set included 30 unrelated individuals from Yoruba in Ibadan, Nigeria (YRI), 30 unrelated Utah residents with ancestry from northern and western Europe (CEU), and a combined group of 45 unrelated Japanese individuals from Tokyo (JPT) and 45 Han Chinese from Beijing (CHB). The genotype data were downloaded directly from the HapMap Project website (see URLs). Our exploratory association analyses of protective alleles with clinical subphenotypes are described in Supplementary Note and Supplementary Table 15 .
Common copy number polymorphisms analysis. For the purpose of this analysis, we used publicly available CNP discovery data obtained with 2.1 million NimbleGen CGH arrays 49, 50 . We identified 1,051 SNPs present on the Illumina HumanHap 610K chip that tag known common (>1%) copy number variations at r 2 > 0.8. The genotypes for these SNPs were extracted from the data set and analyzed separately for association with the disease state ( Supplementary Fig. 4 and Supplementary Table 12) . These SNPs underwent all quality control steps as outlined above before association analysis. A simple 1degreeoffreedom χ 2 allelic test was used to screen for association (PLINK) and the results were ranked and visualized using a quantilequantile plot (R). The top associated CNPs were validated using quantitative realtime PCR.
Quantitative real-time PCR. Quantitative realtime PCR was carried out on genomic DNA using the iQ5 RealTime PCR Detection System (BioRad) and amplification was achieved using SYBR Green Supermix (BioRad) with a stand ard twostep amplification protocol. All samples were analyzed in triplicate. Three amplicons spanning CFHR1 and CFHR3 were tested and the signal was normal ized to an amplicon in Bactin (Supplementary Table 17) . Pooled DNA from ten individuals homozygous for G alleles at rs6677604 was used as reference.
Protein blotting. Diluted plasma samples were separated on 4-15% Ready Gel (BioRad), transferred to PVDF membranes (Millipore), and protein blotted with primary antibodies to CFH (AbD Serotec) and CFHR1 (R&D Systems) using standard protocols.
